Fundies. English
Curative Biotechnology, Inc
EDGAR3 filing records in this dataset, filed from 2022-04-15 to 2024-05-06. Reported financial figures are available; chart coverage varies by period.
Holdings and insider activity
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Insider filings have not been processed for this company yet.
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 903 million shares Source
Exact value
903263385 shares
Reported share-count change
55.93% · 324 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2024-05-06.
Financial data available through: 2023-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 4 of 11 periods available· newest 2023-12-31
- Net income: 4 of 11 periods available· newest 2023-12-31
- Operating cash flow: 4 of 11 periods available· newest 2023-12-31
- Capital expenditure: 1 of 11 periods available· newest 2021-12-31
- Total assets: 4 of 11 periods available· newest 2023-12-31
- Total liabilities: 4 of 11 periods available· newest 2023-12-31
- Current assets: 4 of 11 periods available· newest 2023-12-31
- Current liabilities: 4 of 11 periods available· newest 2023-12-31
- cash and cash equivalents: No compatible figures in this window
- long term debt: No compatible figures in this window
- Shares outstanding: 4 of 11 periods available· newest 2023-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 1.38 millionPrior period
−USD 5.38 million
–
Current period
−USD 4 million
–
Exact inputs and evidence
-4000000 − -5380415 = 1380415 USD
-5380415 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-4000000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 999,434Prior period
−USD 1.5 million
–
Current period
−USD 500,000
–
Exact inputs and evidence
-500000 − -1499434 = 999434 USD
-1499434 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source-500000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | −USD 4.67 million Exact valueExact value: -4670255 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 190,093 Exact valueExact value: -190093 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 5.3 million Exact valueExact value: -5300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.6 million Exact valueExact value: -1604035 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,834 Exact valueExact value: 6834 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.61 million Calculation and evidence-1604035 − 6834 USD Exact free cash flow: -1610869 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 5.38 million Exact valueExact value: -5380415 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.5 million Exact valueExact value: -1499434 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 4 million Exact valueExact value: -4000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 500,000 Exact valueExact value: -500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
3 filings · 212 latest values · 212 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001400271, 1400271, edgar:1400271
Also known as Connectyx Technologies Corp, Curative Biotechnology Inc, Curative Biotechnology, Inc, Curative Biotechnology, Inc.